• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sirtex SIR-Spheres fail to improve survival in colorectal trial

May 18, 2017 By Fink Densford

Sirtex Medical (ASX:SRX) saw shares tumble more than 25% today after a trial of its radioactive microspheres reported no effect in improving survival in patients with colorectal cancer.

Results from the Foxfire analysis study indicated that the use of SIR-Spheres Y-90 microspheres in combination with chemotherapy did not improve overall survival in patients with unresectable colorectal cancer compared to chemotherapy alone, the Woburn, Mass.-based company said.

While it wasn’t shown to improve overall survival, Sirtex said that data from the trial indicated that patients with cancer originating within the right side of the colon may gain more of a benefit from the spheres than chemotherapy alone.

“While these results are not what we expected, we believe that SIR-Spheres Y-90 resin microspheres will continue to play an important role in the treatment of patients with metastatic colorectal cancer. We are committed to helping people with advanced colorectal cancer and look forward to additional validation of this potentially significant finding to improve survival in patients with right-sided colon cancer in the first-line setting. Understanding why patients with right-sided colon cancer do not respond as well to certain drug regimens is currently one of the most actively investigated and controversial conundrums in the gastrointestinal oncology field. We have known for several years that patients with right-sided colon cancer that metastasizes generally have a poorer prognosis than those with left-sided disease. If our initial findings are confirmed, a five-month improvement in median survival in the first line setting could be seen as clinically meaningful in this difficult-to-treat population with liver metastases. This is an important time for the Sirtex Americas team. Every trial provides us with valuable information on how our product should be used and which patient populations may benefit the most. We are confident that our experienced customer-facing team can continue to educate on the recent NCCN Category 2A recommendation in the chemo-refractory population and use the emerging data from the Foxfire Combined Analysis to identify the most appropriate patients to benefit from our product in the earlier setting,” Sirtex Americas senior VP Gary Donofrio said in a press release.

Shares in Sirtex fell 28.3% today, down $4.25 to close at $10.75.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology Tagged With: Sirtex Medical

IN CASE YOU MISSED IT

  • Senseonics stock is up on Q2 results
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS